Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the selection of patients for EGFR-targeted therapy...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gattenlöhner, S., Etschmann, B., Kunzmann, V., Thalheimer, A., Hack, M., Kleber, G., Einsele, H., Germer, C., Müller-Hermelink, H. -K.
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi Publishing Corporation 2009
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837901/
https://ncbi.nlm.nih.gov/pubmed/20300583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/831626
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares